Creo Medical Share Discussion Threads

[edwardt] 23/5/2022 08:16

maybe but on half the rating of sales to intuitive, i would have thought we should be on a higher ev/sales given the opportunity set given the gearing to this announcement. i guess there is a risk of having to follow your money but as this is now getting into bed with the big boys, i will be happy to write a cheque as and when.

[buywell3] 23/5/2022 07:53

Yes but all they have committed to is to clinical trials of certain parts of CREO technology

' the Agreement provides a framework to allow joint clinical studies to be undertaken'

Clinical trials take years

Sorry to pour cold water on any ramps but Intuitive can't afford to take any risk whatsoever regarding CREO technology until it is well proven via the clinical pathway that Intuitive will dictate

Clinical trials are also very costly

Meantime despite recent acquisition/s CREO losses continue to rise ie from todays Finals:

Operating loss of £29.9m for FY 2021 (FY 2020: £23.5m)

Plus the cost of additional training is also going to add --- as is the cost of sales staff

From the Finals today :

· Pipeline of clinicians to be trained under Clinical Education Programme has doubled

· 25% increase in the Group's direct sales force since the start of 2021





buywell wonders if the recent Institutional seller will now sell more ?

dyor

[40 fathoms] 23/5/2022 07:12

Todays RNS highlighting the partnership with Intuitive is excellent indeed. As partners go it would be impossible to do better.

[buywell3] 10/5/2022 22:36

What a ridiculously long thread header

No wonder not many people can be bothered posting





A cash flow statement (CFS) is a financial statement that summarizes the amount of cash and cash equivalents entering and leaving a company.

The CFS measures how well a company manages its cash position, meaning how well the company generates cash.

The CFS complements the balance sheet and the income statement.


advfn data:

Creo Medical Cash Flow Statement

.....30 Jun 2018 (GBP) .. 31 Dec 2018 (GBP) .. 31 Dec 2019 (GBP).. 31 Dec 2020 (GBP)
Operating CF -7.00 ............-14.30.......... -11.85 .............. -16.28 m
Pre-Financing CF -7.78........ -15.58 ..........-12.66 ...............-37.25 m
Retained CF ...-7.32 ...........30.90 ...........36.46................-35.92 m




Operations Cash Flow
Operations Cash Flow is the net cash inflow/outflow from operating activities.


Pre Financing Cash Flow
Pre Financing Cash Flow is the net cash inflow/outflow before financing. Financing includes for example issue of ordinary share capital, debt due within/after one year and capital element of finance lease rental payments.

Retained Cash Flow
Retained Cash Flow is the net increase/decrease in cash and cash equivalents in the financial period.

[hybrasil] 21/3/2022 11:08

Why is this falling so much?

[mw8156] 06/2/2022 22:31

forecast expected to be 25.9m since the last few months of 2021 so if anything sales coming in slightly below if they are just over 25m?

[edwardt] 04/2/2022 15:55

Anyone know what consensus sales actually were? The 25m clearly way above whatever it was...

[aspringo] 04/2/2022 15:03

I'm only down a little bit now ??

[edwardt] 04/2/2022 13:15

This could only be start but mr market is finally awake to this one

[edwardt] 03/2/2022 08:18

25m sales. should properly motor now

[pecuniarum copia] 20/1/2022 11:55

08:47:18 - 125.5 - 2,041,097 - 124.0/127.0 - £2,561,576.74

[edwardt] 20/1/2022 09:14

that's a big overhang cleared.

[il professore] 06/11/2021 18:23

I disagree and am still bullish. Unique technology protected by families of patents. Not sure Creo would have fared like this if they’d listed in the US.

[sinzu] 04/11/2021 12:23

A lot of air to be deflated yet I think. If any IIs' start losing faith here then the share price is going to drop like a stone IMHO.

[sinzu] 29/10/2021 19:33

Like others here, I was encouraged to make an investment through BG’s involvement and following my own research, I also invested. No doubt that they have some very innovative, class leading products, but those latest revenue figures are atrocious and it now looks a hard road ahead. I’m out until I see evidence of decent revenue growth.

[networker] 29/10/2021 18:44

At the closing bid price of 154p, the shares are now at a 16 per cent discount to the recent Placing and Open Offer price of 182.5p, which was itself at a discount to the then market price. Is anyone aware why there is such price weakness? Certainly those institutions who participated in the £30m fundraising can't be over impressed and don't seem to be topping up at all.

[il professore] 26/10/2021 19:51

Truly novel technology with a slow roll out. Will save billions in cost of medical treatment and thousands of lives. I’m seeing a rapid recovery in share price over the next 2-3 months.

[dbfromgb] 05/10/2021 16:52

Indeed. Proactive interview on YouTube has the CEO eulogising about the companies products and their sales network/capabilities, but the latest broker forecasts are indicating minimal changes to revenue over the next couple of years, continuing heavy losses, with most revenue continuing to come from the acquired operations rather than their own core products. Something doesn't smell right. My attempt to ask the company about their commercialisation plans (rather than their product development), and move into future profit, was effectively blocked politely by their NOMAD. Yet their institutional shareholder base has supported the recent fundraising - so what do they know that we don't? I sold out a substantial position a couple of months ago but continue to follow the share in case I have missed something. Imho, dyor

[2theduke] 30/9/2021 07:48

“ Total sales for the period were £12.9m (six months to 30 June 2020: £0.0m) of which £12.8m was generated through the former Albyn group with £0.1m generated through Creo Medical Limited.”
Wow, zero income from their own products. Lucky they used money for an acquisition in my view, this stinks.

[edwardt] 27/8/2021 12:58

in for a penny. i have taken my allocation and some excess too.

[capt bligh] 17/8/2021 09:32

I bought some of these today...looks very nicely poised

[rambutan2] 12/8/2021 22:14

Cash for growth:

Proposed Placing to raise a minimum of GBP30 million

Launch of Accelerated Book Build

Proposed Open Offer to raise up to approximately GBP5 million

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy is pleased to announce a proposed Placing by way of an accelerated bookbuild to raise a minimum of GBP30 million (before expenses) via a conditional placing of new Ordinary Shares at the issue price of 182.5p per share to new and existing institutional investors, to support further growth of the Group and development of its business. The accelerated book build process is expected to close on 13 August 2021, following which the final quantum of the Placing proceeds will be announced.

Furthermore, the Company is proposing to raise up to approximately GBP5 million by way of an Open Offer which will be available to all Qualifying Shareholders on the Record Date.

[rambutan2] 10/6/2021 21:26

Concise presentation from the Cenkos event on tues: